Rockville MD (May 13, 2024) - Cellphire Therapeutics, a leading biotechnology company pioneering innovative solutions in hemostasis and transfusion medicine, is proud to announce a strategic partnership with Vitalant, one of the nation’s largest nonprofit blood and biotherapies healthcare organizations. The partnership includes an initial investment by Vitalant and support for Cellphire's product development and clinical manufacturing processes of its freeze-dried platelet derived hemostat (FPH) and Cryopreserved Platelets.
The partnership with Vitalant underscores a shared commitment to revolutionizing hemostasis solutions and improving patient outcomes. By leveraging Vitalant's expertise and resources, Cellphire is poised to accelerate the development and clinical manufacturing of its groundbreaking FPH product, which has the potential to transform the standard of care for patients requiring hemostatic interventions.
"This strategic partnership marks a significant milestone in Cellphire's mission to advance freeze-dried platelet derived hemostat technology and address critical unmet needs in healthcare,” said Mike Gaffney, Chief Executive Officer of Cellphire Therapeutics. "Vitalant’s blood and biotherapies capabilities in key markets are a resource that strengthens our ability to bring life-saving innovations to patients in need."
As a critical supplier for Cellphire's product development and clinical manufacturing processes, Vitalant plays a pivotal role in supporting the advancement of Cellphire's groundbreaking hemostasis solutions. The investment will fuel Cellphire's efforts to expand its manufacturing capabilities and progress through clinical development and regulatory approval pathways.
"Aligned with our focus on supporting the development of novel blood component products to help save and sustain more lives, we are pleased to support Cellphire Therapeutics’ pioneering work in hemostasis and transfusion medicine," said Ralph Vassallo, M.D., Chief Medical & Scientific Officer of Vitalant. "Through this partnership, we aim to help drive innovation, improve patient care, and advance the field of hemostasis."
About Cellphire Therapeutics: Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is FPH, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications for Orphan populations to surgical, trauma, traumatic brain injury (TBI) and intercranial hemorrhage (ICH) unmet clinical needs, among other things. For more information, visit www.cellphire.com.
About Vitalant: Vitalant is one of the nation’s largest nonprofit blood and biotherapies healthcare organizations, providing hospitals and patients across the U.S. a safe blood supply, specialized laboratory services, transfusion medicine expertise, and world-renowned research. Individuals generously donating blood, volunteering, and giving financially are essential to our lifesaving mission. Learn more at vitalant.org.
Contact Information:
Cellphire Therapeutics contact:
Robert Woods
Vice President, Business Operations
Cellphire Therapeutics